High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 1, 2014, Pages 47.e9-47.e14

  Raman, Jay D ^a   Lin, Yu Kuan ^a   Kaag, Matthew ^a   Atkinson, Timothy ^b   Crispen, Paul ^b   Wille, Mark ^c   Smith, Norm ^d   Hockenberry, Mark ^e   Guzzo, Thomas ^e   Peyronnet, Benoit ^f   Bensalah, Karim ^f   Simhan, Jay ^g   Kutikov, Alexander ^g   Cha, Eugene ^h   Herman, Michael ^h   Scherr, Douglas ^h   Shariat, Shahrokh F ^h   Boorjian, Stephen A ⁱ  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^c Division of Medical Toxicology   (United States)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITÉ DE RENNES 1   (France)

^g FOX CHASE CANCER CENTER   (United States)

^h WEILL CORNELL MEDICAL CENTER   (United States)

ⁱ MAYO CLINIC   (United States)

Author keywords

Clavien complications; Locally advanced disease; Perioperative chemotherapy; Renal function changes; Urothelial carcinoma

Indexed keywords

CISPLATIN; GEMCITABINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CAUSE OF DEATH; CLAVIEN SYSTEM; COHORT ANALYSIS; DETERIORATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HUMAN; KIDNEY FUNCTION; LYMPH NODE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEPHROURETERECTOMY; PEROPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RADICAL NEPHROURETERECTOMY; SCORING SYSTEM; SENESCENCE; TRANSITIONAL CELL CARCINOMA; VERY ELDERLY;

CLAVIEN COMPLICATIONS; LOCALLY ADVANCED DISEASE; PERIOPERATIVE CHEMOTHERAPY; RENAL-FUNCTION CHANGES; UROTHELIAL CARCINOMA;

AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FUNCTION TESTS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEPHRECTOMY; OUTCOME ASSESSMENT (HEALTH CARE); POSTOPERATIVE COMPLICATIONS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; URETER; UROLOGIC NEOPLASMS;

EID: 84890792345     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.06.015     Document Type: Article

References (29)

1. Raman J.D., Scherr D.S. Management of patients with upper urinary tract transitional cell carcinoma. Nat Clin Pract Urol 2007, 4:432.
2. Hall M.C., Womack S., Sagalowsky A.I., et al. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 1998, 52:594.
3. Brown G.A., Busby J.E., Wood C.G., et al. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: time to change the treatment paradigm?. BJU Int 2006, 98:1176.
4. Margulis V., Shariat S.F., Matin S.F., et al. Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer 2009, 115:1224.
5. Yagoda A. Chemotherapy of urothelial tumors. Cancer 1987, 60:574.
6. Grossman H.B., Natale R.B., Tangen C.M., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Eng J Med 2003, 349:859.
7. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomized controlled trial. Lancet 1999, 354:533. International Collaboration of Trialists.
8. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systemic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005, 48:202. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration.
9. Igawa M., Urakami S., Shiina H., et al. Neoadjuvant chemotherapy for locally advanced urothelial cancer of the upper urinary tract. Urol Int 1995, 55:74.
10. Matin S.F., Margulis V., Kamat A., et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract urothelial carcinoma. Cancer 2010, 116:3127.
11. Hellenthal N.J., Shariat S.F., Margulis V., et al. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the upper tract urothelial carcinoma collaboration. J Urol 2009, 182:900.
12. Kwak C., Lee S.E., Jeong I.G., et al. Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract. Urology 2006, 68:53.
13. Vassilakopoulou M., de la Motte Rouge T., Colin P., et al. Outcomes after adjuvant chemotherapy in treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC). Cancer 2011, 117:5500.
14. Bamias A., Deliveliotis C.H., Fountzilas G., et al. Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group. J Clin Oncol 2004, 22:2150.
15. Rink M., Fajkovic H., Cha E.K., et al. Death certificates are valid for the determination of the cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol 2012, 61:854.
16. Dindo D., Demartines N., Clavien P.A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004, 240:205.
17. Donat S.M., Shabsigh A., Savage C., et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol 2009, 55:177.
18. Canter D., Long C., Kutikov A., et al. Clinicopathologic outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU Int 2011, 107:58.
19. Svatek R.S., Shariat S.F., Lasky R.E., et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res 2010, 16:4461.
20. Rink M., Sjoberg D., Comploj E., et al. Risk of cancer-specific mortality following recurrence after radical nephroureterectomy. Ann Surg Oncol 2012, [Epub ahead of print].
21. Lane B.R., Smith A.K., Larson B.T., et al. Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer 2010, 116:2967.
22. Kaag M.G., O'Malley R.L., O'Malley P.O., et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol 2010, 58:581.
23. Costantini C., Millard F. Update on chemotherapy in the treatment of urothelial carcinoma. Sci World J 2011, 11:1981.
24. Rassweiler J.J., Schulze M., Marrero R., et al. Laparoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma: is it better than open surgery?. Eur Urol 2004, 46:690.
25. Clements T., Messer J.C., Terrell J.D., et al. High-grade ureteroscopic biopsy is associated with advanced pathology of upper-tract urothelial carcinoma tumors at definitive surgical resection. J Endourol 2012, 26:398.
26. Brien J.C., Shariat S.F., Herman M.P., et al. Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol 2010, 184:69.
27. Margulis V., Youssef R.F., Karakiewicz P.I., et al. Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J Urol 2010, 184:453.
28. Favaretto R.L., Shariat S.F., Savage C., et al. Combining imaging and ureteroscopy variables in a preoperative multivariate model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. BJU Int 2011, 109:77.
29. Messer J., Lin Y.K., Raman J.D. The role of lymphadenectomy for upper tract urothelial carcinoma. Nat Rev Urol 2011, 8:394.